Background
==========

Endogenous fungal endophthalmitis is a rare, potentially blinding complication of systemic fungal infection. Overall, the commensal yeast *Candida albicans* is the most common fungal isolate in patients with endogenous fungal endophthalmitis, although other *Candida* strains have been implicated as causative organisms including *Candida tropicalis*, *Candida parapsilosis*, *Candida glabrata*, *Candida guilliermondii*, *Candida krusei*, and more recently *Candida dubliniensis*\[[@B1]\]*. C. dubliniensis* was first identified in 1995 in Ireland as an oral commensal isolated from HIV-infected individuals and has since been isolated in a variety of other candidal infections \[[@B2]\]. Although *C. dubliniensis* was initially identified as an 'atypical' form of the more common *C. albicans*, subsequent phenotypic and genotypic studies have identified it as a separate strain \[[@B2]\]. Further studies have shown that *C. dubliniensis* and *C. albicans* differ not only phenotypically but also in terms of epidemiology, virulence characteristics, and the ability of *C. dubliniensis* to develop fluconazole resistance \[[@B3]\]. Due to these variations, it is important to differentiate these strains in clinical situations like *Candida* endophthalmitis due to potential differences in presentation, treatment, and clinical outcomes. To our knowledge, there have been only three previously reported cases of endophthalmitis caused by *C. dubliniensis* since the discovery of the organism \[[@B4]-[@B6]\]. We report and discuss the significance of five new cases of *C. dubliniensis* endophthalmitis identified over 15 years in public hospitals in Queensland, Australia.

Methods
=======

Queensland public hospital pathology records were reviewed for all patients with endophthalmitis and vitreous/aqueous samples that cultured *C. dubliniensis* over a 15-year period from June 1998 to June 2013. Five patients were identified over this period. The medical records of these patients were then retrospectively reviewed for demographic data, background medical history, presenting signs and symptoms, diagnostic testing, microbiology results, treatment received, visual outcome, and mortality. This review was conducted in accordance with guidelines set forth by the Declaration of Helsinki and was exempt from institutional review board approval.

Results
=======

Age, sex, and predisposing factors
----------------------------------

Six eyes from four males and one female aged from 21 to 55 years (mean 37 years) were identified for our series (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). All patients had endogenous endophthalmitis, but only two patients had other symptoms of systemic illness with the other three patients having isolated endophthalmitis only. Four patients had a background of intravenous drug use (80%), four patients had hepatitis C (80%), one patient had associated liver cirrhosis (20%), and one patient had associated *Candida* endocarditis (20%). The four patients with hepatitis C were not being treated with antiviral therapy at the time of presentation. Two patients had intravenous lines *in situ* at the time of presentation (40%). All five patients had no previous ophthalmic history, and all had best-corrected visual acuities of better than 20/32 in both eyes before presentation for endophthalmitis.

###### 

**Endogenous*C. dubliniensis*endophthalmitis cases**

  **Case (reference)**                **Sex, age**   **Comorbidities**                                   **Site**    **Referral pathway**         **Initial visual acuity**     **Antifungal sensitivity**                                 **Antifungal treatment and surgery**                                                                                                            **Final visual acuity**
  ----------------------------------- -------------- --------------------------------------------------- ----------- ---------------------------- ----------------------------- ---------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------
  Sedeek, 2008 \[[@B4]\]              M, 38          Nil                                                 Right eye   Not reported                 VA RE - HM, LE - 20/20        Fluconazole, voriconazole, caspofungin, amphotericin B     Urgent lensectomy/vitrectomy, IVI vancomycin/ceftazidime. IVI/topical amphotericin B, PO voriconazole (no duration)                             Not reported
  Pelegrin, 2010 \[[@B5]\]            M, 41          IVDU, HIV+, hepatitis B and C, fever, neutropenia   Right eye   Presented to eye emergency   VA RE - 20/200, LE - 20/400   Azoles                                                     Vitrectomy, IVI amphotericin B. Systemic voriconazole then PO fluconazole for 2 months                                                          VA RE - 20/60
  Espinosa-Heidmann, 2012 \[[@B6]\]   M, 27          IVDU, onychomycosis                                 Left eye    Presented to eye clinic      VA LE - 20/400                Fluconazole and all other agents tested                    Toxoplasma treatment. IV fluconazole. Vitrectomy/IVI amphotericin B. PO fluconazole for 6 weeks                                                 VA LE - 20/80
  Present case 1                      M, 50          IVDU, hepatitis C                                   Right eye   Walk-in to eye outpatients   VA RE - CF, LE - 20/20        Fluconazole, 5-flucytosine, voriconazole, amphotericin B   Empirical IVI amphotericin B. Vitrectomy. 2× IVI amphotericin B. PO voriconazole for 46 days                                                    VA RE - 20/30, LE - 20/16
  Present case 2                      M, 28          IVDU                                                Right eye   Walk-in to eye outpatients   VA RE - 20/200, LE - 20/20    Fluconazole, 5-flucytosine, voriconazole                   Urgent vitrectomy/IVI voriconazole. Empirical systemic voriconazole. 3× IVI amphotericin B. Vitrectomy/buckle/gas. PO fluconazole for 42 days   VA RE - 20/60, LE - 20/20
  Present case 3                      M, 34          IVDU, hepatitis C, endocarditis, PICC               Right eye   Inpatient referral           VA RE - HM, LE - 20/60        Fluconazole, 5-flucytosine, voriconazole                   Empirical fluconazole, IVI amphotericin B. 2× IVI amphotericin B. Vitrectomy. PO voriconazole for 35 days. Vitrectomy/buckle/gas                VA RE - HM, LE - 20/20
  Present case 4                      M, 55          T2DM, hepatitis C, liver cirrhosis, PICC            Bilateral   Inpatient referral           VA RE - 20/200, LE - 20/200   Fluconazole, 5-flucytosine, voriconazole, amphotericin B   Empirical fluconazole. Right vitrectomy. 10× IVI voriconazole RE. 4× IVI voriconazole LE. Left vitrectomy. PO fluconazole for 42 days           VA RE - 20/60, LE - 20/60
  Present case 5                      F, 21          IVDU, hepatitis C                                   Left eye    Walk-in to eye outpatients   VA RE - 20/18, LE - 20/200    Fluconazole, 5-flucytosine, voriconazole, amphotericin B   Empirical voriconazole, IVI amphotericin B. 8× IVI voriconazole. Vitrectomy. PO fluconazole for 36 days                                         VA RE - 20/16, LE - 20/30

*Abbreviations:CF* counting fingers, *F* female, *HM* hand movements, *IVDU* intravenous drug use, *IVI* intravitreal injection, *LE* left eye, *M* male, *PICC* peripherally inserted central catheter, *PO* per oral, *RE* right eye, *T2DM* type 2 diabetes mellitus, *VA* visual acuity.

###### 

**Summary statistics for endogenous*C. dubliniensis*endophthalmitis**

                                                           **Queensland series**   **Previous endogenous cases**   **Total**
  ------------------------------------------------------- ----------------------- ------------------------------- ------------
  Number of patients                                                 5                           3                     8
  Number of eyes involved                                            6                           3                     9
  Diagnosis and microbiology                                                                                            
   Vitreous taps                                                     5                           1                     6
   Positive fungal vitreous taps                                  3 (60%)                    1 (100%)               4 (67%)
   Vitrectomy specimens                                              7                           3                     10
   Positive fungal vitrectomy specimens                           3 (43%)                    3 (100%)               6 (60%)
  Ocular treatment                                                                                                      
   Intravitreal amphotericin (number of eyes)                     3 (50%)                     2 (66%)               5 (56%)
   Intravitreal voriconazole (number of eyes)                     4 (66%)                        0                  4 (44%)
   Urgent vitrectomy                                              1 (17%)                     1 (33%)               2 (22%)
   Total number of vitrectomies                                      8                           3                     11
  Systemic treatment                                                                                                    
   Empirical fluconazole                                          2 (40%)                     1 (33%)               3 (38%)
   Empirical voriconazole                                         2 (40%)                     1 (33%)               3 (38%)
   Definitive fluconazole therapy                                 3 (60%)                     2 (66%)               5 (56%)
   Definitive voriconazole therapy                                2 (40%)                     1 (33%)               3 (33%)
   Mean duration of antifungal treatment (days)                     40                          49                     43
  Outcomes                                                                                                              
   Mean duration of follow-up (days)                                345                         56                    287
   Final best-corrected visual acuity better than 20/80           5 (83%)                    2 (100%)              7 (87%)^a^
   Final best-corrected visual acuity worse than 20/200           1 (17%)                        0                 1 (13%)^a^
   Retinal detachment                                             2 (33%)                        0                  2 (22%)
   Enucleation/evisceration                                          0                           0                     0
   Mortality                                                         0                           0                     0

^a^Details of final visual acuity have been described only in eight cases.

Presentation and diagnosis
--------------------------

In terms of referral pathway, three patients presented to the hospital ophthalmology outpatient department with a mean time from onset of symptoms to ophthalmologic review of 6.3 days. Two patients were current hospital inpatients, and the mean time from onset of symptoms to ophthalmologic review in these patients was 1 day. The right eye was affected in three cases and the left eye in one case, and there was one case of bilateral endophthalmitis. Visual acuity was 20/200 or worse in the affected eye in all patients at presentation (Table [1](#T1){ref-type="table"}). The major presenting symptom in all cases was decreased visual acuity. On examination, all patients had severe anterior chamber inflammation and severe vitritis. No patient presented with hypopyon. Two patients had evidence of vitreous snowballs.

Diagnostic testing and microbiology
-----------------------------------

Systemically, all patients had blood cultures, HIV serology, and echocardiography on presentation. A total of 19 blood cultures were collected from the five patients (mean 3.8 per patient, range 1--8). Only 4 of these 19 cultures were positive for *C. dubliniensis* (22%), and all 4 of these were collected from the patient with bilateral endophthalmitis. All patients were HIV negative on serology at the time of presentation. Echocardiography showed associated endocarditis in one patient.

In terms of ophthalmic investigations, between the six eyes, five vitreous taps were performed with three samples (60%) producing positive *C. dubliniensis* cultures. No anterior chamber taps were performed. Seven vitrectomy samples were taken from the six eyes with three intraoperative vitreous samples (43%) producing positive *C. dubliniensis* cultures. The mean length of time for notification of a positive vitreous *C. dubliniensis* culture was 5.4 days (range 3--10 days). In terms of antifungal sensitivities, all six isolates were sensitive to fluconazole, 5-flucytosine, and voriconazole; however, only three isolates were sensitive to amphotericin B.

Treatment
---------

In terms of initial treatment, five eyes (83%) from four patients were treated with vitreous tap, intravitreal injection of an antifungal agent, and systemic antifungal therapy on the day of presentation. One eye from one patient was initially treated with urgent vitrectomy, intravitreal injection of an antifungal agent, and systemic antifungal therapy on the day of presentation (17%).

Systemically, the empirical antifungal agent administered was fluconazole in two patients (40%), voriconazole in two patients (40%), and amphotericin B in one patient. Once positive *C. dubliniensis* culture was obtained, three patients were treated with systemic fluconazole (60%) and two patients were treated with systemic voriconazole (40%). For the patients treated with fluconazole, the mean duration of treatment was 40 days (range 36--42 days). For the patients treated with voriconazole, the mean duration of treatment of 40.5 days (range 35--46 days).

In terms of ophthalmic treatment, all six infected eyes received intravitreal antifungal injections. A total of 33 intravitreal injections were given - 22 voriconazole and 11 amphotericin B. The mean number of intravitreal injections per eye was 5.5 (range 3--10), and the mean interval between intravitreal injections was 4.2 days.

All eyes underwent vitrectomy at least once for clearance of infection. The mean time from onset of symptoms to the first vitrectomy was 20.5 days (range 1--43 days). Only one vitrectomy was performed urgently on the day of presentation for diagnosis and for early clearance of infection due to extensive vitreous snowballs. In total, eight vitrectomies were performed on the six eyes - two eyes required two vitrectomies due to subsequent retinal detachments which required repair.

Visual outcomes and mortality
-----------------------------

There was no associated mortality in our series, and no infected eye required enucleation or evisceration. No patient developed any secondary fungal infection during follow-up or experienced any systemic complications.

In terms of visual outcomes, five eyes (83%) recovered best-corrected visual acuity of 20/60 or better and one eye had a poor final visual acuity of hand movements only. No eyes developed associated cataract or glaucoma. Two eyes did develop retinal detachment over the course of the endophthalmitis which required surgical repair. Both detachments were caused by single superior retinal tears. The maculae were still attached on the day of diagnosis and repair in both cases. The first of these two patients had initially undergone urgent vitrectomy on the day of presentation, and subsequent retinal detachment occurred 10 days later. This patient eventually had final best-corrected visual acuity of 20/60. The second patient had an initial vitrectomy 12 days after presentation and developed retinal detachment 2 days later. This patient eventually had final best-corrected visual acuity of hand movements only.

Discussion
==========

It is well documented that *Candida* species are among the most common known fungal pathogens. They can cause a wide range of diseases in humans from superficial mucosal infections to life-threatening disseminated diseases. By far, the most prevalent isolated strain is *C. albicans* which has been implicated in up to 65% of cases of candidemia \[[@B7]\]. Although *C. albicans* has been shown to have low virulence in healthy individuals, candidemia is associated with relatively high rates of morbidity and mortality \[[@B8]\]. Among patients with diagnosed candidemia, reported rates of associated endogenous endophthalmitis range from less than 3% to 44% and mortality rates in these patients have been reported as high as 77% \[[@B9]\]. *Candida* species reported to cause endophthalmitis include *C. albicans*, *C. tropicalis*, *C. parapsilosis*, *C. glabrata*, *C. guilliermondii*, *C. krusei*, and most recently *C. dubliniensis*.

*C. dubliniensis* was first described in 1995 in Dublin, Ireland, among HIV-infected patients with oral candidiasis \[[@B2]\]. It has been found to be only a minor component of the oral flora of humans, and although it primarily causes oral candidiasis in HIV-infected and immunocompromised patients, rare reports of invasive systemic infections in both HIV-positive and HIV-negative patients have been documented \[[@B10]-[@B12]\]. This is consistent with large epidemiological studies which report that candidemia caused by *C. dubliniensis* has only rarely been identified and represents around 2% of yeast-positive blood cultures \[[@B7]\]. The rare isolation of *C. dubliniensis* has also likely been due to its close phenotypic similarity to *C. albicans* resulting in often misidentification in laboratory settings. In fact, retrospective studies of *Candida* isolates in fungal stock collections going back to the 1970s have since found many cases of *C. dubliniensis* that were mistakenly identified as *C. albicans*\[[@B13]-[@B15]\]. This suggests that *C. dubliniensis* has probably been present in the community for a much longer period than its recent discovery indicates and could also suggest that many cases of *C. dubliniensis* endophthalmitis have been wrongly attributed to *C. albicans* in previous published literature.

Thus, due to its rare nature, only recent identification, and probable previous misidentification, *C. dubliniensis* has only rarely been reported as the causative organism in endophthalmitis. Although the sample size of our series is small, surprisingly, our five cases of *C. dubliniensis* endophthalmitis represent the largest single case series published to date with only three other previously reported cases to our knowledge in the literature (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) \[[@B4]-[@B6]\]. The significance of these now eight total cases is important because recent studies have shown that *C. dubliniensis* is less pathogenic than *C. albicans* and this may have implications for the diagnosis and treatment of endophthalmitis caused by these separate organisms.

Comparing the five cases in our series with the three previous cases (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}), it is clear that risk factors for endogenous *C. dubliniensis* endophthalmitis include male gender, intravenous drug use, hepatitis, liver disease, placement of an intravenous catheter, and endocarditis. It is also important to note that only one previous patient has been HIV positive \[[@B5]\]. In terms of presentation, often these cases present as isolated endophthalmitis infections without any other systemic evidence of disseminated disease.

Diagnosis in *C. dubliniensis* endophthalmitis can be difficult because the organism has high false-negative rates on fungal cultures of both vitreous samples and blood cultures. However, the sensitivities of these investigations in our series were improved compared to previous *C. albicans* endophthalmitis series \[[@B16]\]. Microbiologically, although fluconazole-resistant isolates of *C. dubliniensis* have been described due to overexpression of genes encoding multidrug transporter proteins \[[@B17]\], all isolates from the reported cases of *C. dubliniensis* endophthalmitis have been susceptible not only to fluconazole but most other conventional antifungal agents (Table [1](#T1){ref-type="table"}).

In terms of treatment and outcomes, vitrectomy, repeated intravitreal injection, and systemic antifungal therapy appear to be efficacious in *C. dubliniensis* endophthalmitis with 87% of infected eyes recovering vision of 20/80 or better. Only retinal detachment appears to be associated with poorer visual outcomes, while surprisingly, early vitrectomy, increased number of intravitreal injections, and delayed presentation all appear to not influence visual outcomes.

Most interestingly, the visual outcomes for endogenous *C. dubliniensis* endophthalmitis appear to be slightly better when compared to a recent study into visual outcomes in endogenous *C. albicans* endophthalmitis cases \[[@B16]\]. In this study, 33% of patients with *C. albicans* endophthalmitis had a final visual acuity of 20/200 or worse and 52% of patients had a final visual acuity of 20/40 or worse \[[@B16]\]. These differences in visual outcomes between *C. dubliniensis* endophthalmitis and the more common *C. albicans* endophthalmitis support the hypothesis suggested by Moran et al. that *C. dubliniensis* is less pathogenic than *C. albicans* due to the decreased ability of *C. dubliniensis* to produce hyphae and its intolerance to environmental stressors \[[@B18]\]. This is further supported by the reduced associated systemic mortality in *C. dubliniensis* endophthalmitis.

Conclusions
===========

Overall, *C. dubliniensis* is a rare cause of both candidemia and endogenous endophthalmitis and can present in both HIV-positive and HIV-negative patients. Based on the albeit limited number of reported endophthalmitis cases caused by this organism, we recommend treatment with intravitreal voriconazole to avoid possible amphotericin B resistance, followed by vitrectomy for clearance of infection and a 6-week course of systemic fluconazole therapy. Although this organism can be resistant to fluconazole, there is no documented case of *C. dubliniensis* endophthalmitis where the isolate has shown this resistance. In addition, although this treatment regime may be complicated by retinal detachment, overall it appears to be associated with improved visual outcomes compared to cases caused by *C. albicans* and does not lead to any associated systemic morbidity or mortality.
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